Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas

Marta Mellai, Angela Piazzi, Valentina Caldera, Laura Annovazzi, Oriana Monzeglio, Rebecca Senetta, Paola Cassoni, Davide Schiffer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The epithelial membrane protein 3 (EMP3) is a candidate tumor suppressor gene in the critical region 19q13.3 for several solid tumors, including tumors of the nervous systems. The aim of this study was to investigate the EMP3 promoter hypermethylation status in a series of 229 astrocytic and oligodendroglial tumors and in 16 GBM cell lines. The analysis was performed by methylation-specific PCR and capillary electrophoresis. Furthermore, the EMP3 expression at protein level was evaluated by immunohistochemistry and Western blotting analysis. Associations of EMP3 hypermethylation with total 1p/19q codeletion, MGMT promoter hypermethylation, IDH1/IDH2 and TP53 mutations, and EGFR amplification were studied, as well as its prognostic significance. The EMP3 promoter hypermethylation has been found in 39.5% of gliomas. It prevailed in low-grade tumors, especially in gliomas with an oligodendroglial component, and in sGBMs upon pGBMs. In oligodendroglial tumors, it was strongly associated with both IDH1/IDH2 mutations and total 1p/19q codeletion and inversely with EGFR gene amplification. No association was found with MGMT hypermethylation and TP53 mutations. In the whole series, the EMP3 hypermethylation status correlated with 19q13.3 loss and lack of EMP3 expression at protein level. A favorable prognostic significance on overall survival of the EMP3 promoter hypermethylation was found in patients with oligodendroglial tumors.

Original languageEnglish
Article number756302
JournalBioMed Research International
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Glioma
Membrane Proteins
Genes
Tumors
Neoplasms
Mutation
Nervous System Neoplasms
erbB-1 Genes
Capillary electrophoresis
Methylation
Gene Amplification
Capillary Electrophoresis
Neurology
Tumor Suppressor Genes
Amplification
Proteins
Western Blotting
Immunohistochemistry
Cells
Association reactions

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Mellai, M., Piazzi, A., Caldera, V., Annovazzi, L., Monzeglio, O., Senetta, R., ... Schiffer, D. (2013). Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas. BioMed Research International, 2013, [756302]. https://doi.org/10.1155/2013/756302

Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas. / Mellai, Marta; Piazzi, Angela; Caldera, Valentina; Annovazzi, Laura; Monzeglio, Oriana; Senetta, Rebecca; Cassoni, Paola; Schiffer, Davide.

In: BioMed Research International, Vol. 2013, 756302, 2013.

Research output: Contribution to journalArticle

Mellai, M, Piazzi, A, Caldera, V, Annovazzi, L, Monzeglio, O, Senetta, R, Cassoni, P & Schiffer, D 2013, 'Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas', BioMed Research International, vol. 2013, 756302. https://doi.org/10.1155/2013/756302
Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R et al. Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas. BioMed Research International. 2013;2013. 756302. https://doi.org/10.1155/2013/756302
Mellai, Marta ; Piazzi, Angela ; Caldera, Valentina ; Annovazzi, Laura ; Monzeglio, Oriana ; Senetta, Rebecca ; Cassoni, Paola ; Schiffer, Davide. / Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas. In: BioMed Research International. 2013 ; Vol. 2013.
@article{81c0fae94c6a453785af662a7f1a52d9,
title = "Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas",
abstract = "The epithelial membrane protein 3 (EMP3) is a candidate tumor suppressor gene in the critical region 19q13.3 for several solid tumors, including tumors of the nervous systems. The aim of this study was to investigate the EMP3 promoter hypermethylation status in a series of 229 astrocytic and oligodendroglial tumors and in 16 GBM cell lines. The analysis was performed by methylation-specific PCR and capillary electrophoresis. Furthermore, the EMP3 expression at protein level was evaluated by immunohistochemistry and Western blotting analysis. Associations of EMP3 hypermethylation with total 1p/19q codeletion, MGMT promoter hypermethylation, IDH1/IDH2 and TP53 mutations, and EGFR amplification were studied, as well as its prognostic significance. The EMP3 promoter hypermethylation has been found in 39.5{\%} of gliomas. It prevailed in low-grade tumors, especially in gliomas with an oligodendroglial component, and in sGBMs upon pGBMs. In oligodendroglial tumors, it was strongly associated with both IDH1/IDH2 mutations and total 1p/19q codeletion and inversely with EGFR gene amplification. No association was found with MGMT hypermethylation and TP53 mutations. In the whole series, the EMP3 hypermethylation status correlated with 19q13.3 loss and lack of EMP3 expression at protein level. A favorable prognostic significance on overall survival of the EMP3 promoter hypermethylation was found in patients with oligodendroglial tumors.",
author = "Marta Mellai and Angela Piazzi and Valentina Caldera and Laura Annovazzi and Oriana Monzeglio and Rebecca Senetta and Paola Cassoni and Davide Schiffer",
year = "2013",
doi = "10.1155/2013/756302",
language = "English",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas

AU - Mellai, Marta

AU - Piazzi, Angela

AU - Caldera, Valentina

AU - Annovazzi, Laura

AU - Monzeglio, Oriana

AU - Senetta, Rebecca

AU - Cassoni, Paola

AU - Schiffer, Davide

PY - 2013

Y1 - 2013

N2 - The epithelial membrane protein 3 (EMP3) is a candidate tumor suppressor gene in the critical region 19q13.3 for several solid tumors, including tumors of the nervous systems. The aim of this study was to investigate the EMP3 promoter hypermethylation status in a series of 229 astrocytic and oligodendroglial tumors and in 16 GBM cell lines. The analysis was performed by methylation-specific PCR and capillary electrophoresis. Furthermore, the EMP3 expression at protein level was evaluated by immunohistochemistry and Western blotting analysis. Associations of EMP3 hypermethylation with total 1p/19q codeletion, MGMT promoter hypermethylation, IDH1/IDH2 and TP53 mutations, and EGFR amplification were studied, as well as its prognostic significance. The EMP3 promoter hypermethylation has been found in 39.5% of gliomas. It prevailed in low-grade tumors, especially in gliomas with an oligodendroglial component, and in sGBMs upon pGBMs. In oligodendroglial tumors, it was strongly associated with both IDH1/IDH2 mutations and total 1p/19q codeletion and inversely with EGFR gene amplification. No association was found with MGMT hypermethylation and TP53 mutations. In the whole series, the EMP3 hypermethylation status correlated with 19q13.3 loss and lack of EMP3 expression at protein level. A favorable prognostic significance on overall survival of the EMP3 promoter hypermethylation was found in patients with oligodendroglial tumors.

AB - The epithelial membrane protein 3 (EMP3) is a candidate tumor suppressor gene in the critical region 19q13.3 for several solid tumors, including tumors of the nervous systems. The aim of this study was to investigate the EMP3 promoter hypermethylation status in a series of 229 astrocytic and oligodendroglial tumors and in 16 GBM cell lines. The analysis was performed by methylation-specific PCR and capillary electrophoresis. Furthermore, the EMP3 expression at protein level was evaluated by immunohistochemistry and Western blotting analysis. Associations of EMP3 hypermethylation with total 1p/19q codeletion, MGMT promoter hypermethylation, IDH1/IDH2 and TP53 mutations, and EGFR amplification were studied, as well as its prognostic significance. The EMP3 promoter hypermethylation has been found in 39.5% of gliomas. It prevailed in low-grade tumors, especially in gliomas with an oligodendroglial component, and in sGBMs upon pGBMs. In oligodendroglial tumors, it was strongly associated with both IDH1/IDH2 mutations and total 1p/19q codeletion and inversely with EGFR gene amplification. No association was found with MGMT hypermethylation and TP53 mutations. In the whole series, the EMP3 hypermethylation status correlated with 19q13.3 loss and lack of EMP3 expression at protein level. A favorable prognostic significance on overall survival of the EMP3 promoter hypermethylation was found in patients with oligodendroglial tumors.

UR - http://www.scopus.com/inward/record.url?scp=84884833048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884833048&partnerID=8YFLogxK

U2 - 10.1155/2013/756302

DO - 10.1155/2013/756302

M3 - Article

C2 - 24083241

AN - SCOPUS:84884833048

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 756302

ER -